Kauvar Arielle N B, Arpey Christopher J, Hruza George, Olbricht Suzanne M, Bennett Richard, Mahmoud Bassel H
*New York University School of Medicine, New York, New York; †New York Laser & Skin Care, New York, New York; ‡Mayo Clinic, Rochester, Minnesota; §St. Louis University, St Louis, Missouri; ‖Laser & Dermatologic Surgery Center, Chesterfield, Missouri; ¶Lahey Clinic; Associate Professor, Harvard Medical School, Boston, Massachusetts; #David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; **Keck School of Medicine, University of Southern California, Los Angeles, California.
Dermatol Surg. 2015 Nov;41(11):1214-40. doi: 10.1097/DSS.0000000000000478.
Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in the United States. Cutaneous squamous cell carcinoma has an estimated incidence of more than 700,000 new cases per year and a 5% risk of metastasis.
To provide clinicians with guidelines for the management of cSCC based on evidence from a comprehensive literature review and consensus among the authors.
The authors conducted an extensive review of the medical literature on treatment methods for cSCC, taking into consideration cure rates, recurrence and metastatic rates, aesthetic and functional outcomes, and cost effectiveness of the procedures.
Surgical treatments provide the best outcomes for cSCC. Mohs micrographic surgery is a cost-effective procedure that affords the highest cure rate, maximal tissue preservation, and superior cosmetic outcomes. Nonsurgical methods may be used as a primary treatment for low-risk squamous cell carcinomas, but the cure rates are lower.
The cure rate remains the most important consideration in choosing the treatment method, but additional factors, such as the patient's general medical condition, psychosocial circumstances, the location of the tumor and cost effectiveness of the therapy should be considered. Mohs micrographic surgery remains the preferred treatment for high-risk tumors and tumors located in cosmetically sensitive areas.
皮肤鳞状细胞癌(cSCC)是美国第二常见的癌症。皮肤鳞状细胞癌的估计年发病率超过70万例,转移风险为5%。
基于全面文献综述的证据和作者之间的共识,为临床医生提供cSCC管理指南。
作者对关于cSCC治疗方法的医学文献进行了广泛综述,考虑了治愈率、复发率和转移率、美学和功能结果以及手术的成本效益。
手术治疗为cSCC提供了最佳结果。莫氏显微描记手术是一种具有成本效益的手术,具有最高的治愈率、最大程度的组织保留和优异的美容效果。非手术方法可作为低风险鳞状细胞癌的主要治疗方法,但治愈率较低。
在选择治疗方法时,治愈率仍然是最重要的考虑因素,但还应考虑其他因素,如患者的总体医疗状况、心理社会情况、肿瘤位置和治疗的成本效益。莫氏显微描记手术仍然是高危肿瘤和位于美容敏感区域的肿瘤的首选治疗方法。